SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment | Morningstar

[GlobeNewswire](/news/globe-newswire) SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment FDA confirms that SciSparc’s study may proceed following the application submission a month ago TEL AV
Read more...